Anal Cancer Market Report provides a detailed analysis of the Anal Cancer Market Size, Epidemiology, Drug therapies, Companies and pipeline for study period from 2020-2034.

Anal Cancer Market Size, Share | Anal Cancer Market Report, Market trends

Anal Cancer Market Infographic

1. Key Insights
2. Report Introduction
3. Executive Summary of Anal Cancer
4. Anal Cancer Market Overview at a Glance
4.1. Market Share by Therapies (%) Distribution of Anal Cancer in 2020 in the 7MM
4.2. Market Share by Therapies (%) Distribution of Anal Cancer in 2034 in the 7MM
5. Key Events
6.&nbsp;Anal cancer Epidemiology and Market Forecast Methodology
7. Disease Background and Overview
7.1. Introduction
7.2. Signs and Symptoms
7.3. Cause and Risk Factors of Anal Cancer
7.4. Types of Anal Cancer
7.5. Pathophysiology of Anal Cancer
7.6. HPV Infection and Anal Cancer
7.7. Staging of Anal Cancer
7.8. Diagnosis
7.8.1. Diagnostic Algorithm
7.8.2. Diagnostic and Screening Guidelines
7.8.2.1. Anal Cancer: ESMO Clinical Practice Guidelines for Diagnosis
7.8.2.2. International Anal Neoplasia Society&rsquo;s Consensus Guidelines for Anal Cancer Screening
7.8.2.3. Anal Cancer Screening and Prevention: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Guidelines
7.8.2.4. Anal Cancer: French Intergroup Clinical Practice Guidelines for Diagnosis (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)
8. Treatment and Management of Anal Cancer
8.1. Treatment Algorithm
8.2. Treatment Guidelines and Recommendations for Anal Cancer
8.3. NCCN Guideline for Anal Cancer (Version 2024)
8.4. ESMO Guideline for Anal Cancer
8.5. German Guideline Program in Oncology (2021)
8.6. The Italian Society of Colorectal Surgery (SICCR): 2012
8.7. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for Anal Squamous Cell Cancers (Revised 2018)
8.8. Anal Cancer: French Intergroup Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
9.&nbsp;Anal cancer Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. Incident Cases of Anal Cancer in the 7MM
9.4. The United States
9.4.1. Incident Cases of Anal Cancer in the United States
9.4.2. Gender-specific Cases of Anal Cancer in the United States
9.4.3. Age-specific Cases of Anal Cancer in the United States
9.4.4. Histology-specific Cases of Anal Cancer in the United States
9.4.5. HPV Status-specific Cases of Anal Cancer in the United States
9.4.6. Stage-specific Cases of Anal Cancer in the United States
9.4.7. Linewise Treated Cases of Anal Cancer in the United States
9.5. EU4 and the UK
9.5.1. Incident Cases of Anal Cancer in EU4 and the UK
9.5.2. Gender-specific Cases of Anal Cancer in EU4 and the UK
9.5.3. Age-specific Cases of Anal Cancer in EU4 and the UK
9.5.4. Histology-specific Cases of Anal Cancer in EU4 and the UK
9.5.5. HPV Status-specific Cases of Anal Cancer in EU4 and the UK
9.5.6. Stage-specific Cases of Anal Cancer in EU4 and the UK
9.5.7. Linewise Treated Cases of Anal Cancer in EU4 and the UK
9.6. Japan
9.6.1. Incident Cases of Anal Cancer in Japan
9.6.2. Gender-specific Cases of Anal Cancer in Japan
9.6.3. Age-specific Cases of Anal Cancer in Japan
9.6.4. Histology-specific Cases of Anal Cancer in Japan
9.6.5. HPV Status-specific Cases of Anal Cancer in Japan
9.6.6. Stage-specific Cases of Anal Cancer in Japan
9.6.7. Linewise Treated Cases of Anal Cancer in Japan
10. Patient Journey
11. Emerging&nbsp;Anal cancer Therapies
11.1. Key Cross of Emerging Therapies
11.2. Retifanlimab: Incyte Corporation
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.4. Clinical Trial Information
11.2.5. Safety and Efficacy
11.3. BMX-001: BioMimetix
11.3.1. Product Description
11.3.2. Clinical Development
11.3.3. Clinical Trial Information
11.3.4. Safety and Efficacy
12. Anal Cancer Market: Seven Major Market Analysis
12.1. Key Findings
12.2. Anal cancer Market Outlook
12.3. Conjoint Analysis
12.4. Key Anal cancer Market Forecast Assumptions
12.5. Total Market Size of Anal Cancer in the 7MM
12.6. Market Size of Anal Cancer by Therapies in the 7MM
12.7. The United States Anal cancer Market Size
12.7.1. Total Market Size of Anal Cancer in the United States
12.7.2. Market Size of Anal Cancer by Therapies in the United States
12.8. EU4 and the UK Anal cancer Market Size
12.8.1. Total Market Size of Anal Cancer in EU4 and the UK
12.8.2. Market Size of Anal Cancer by Therapies in EU4 and the UK
12.9. Japan Anal cancer Market Size
12.9.1. Total Market Size of Anal Cancer in Japan
12.9.2. Market Size of Anal Cancer by Therapies in Japan
13.&nbsp;Anal cancer Unmet Needs
14.&nbsp;Anal cancer SWOT Analysis
15.&nbsp;Anal cancer KOL Views
16.&nbsp;Anal cancer Market Access and Reimbursement
16.1. United States
16.1.1. Centre for Medicare and Medicaid Services (CMS)
16.2. EU4 and the UK
16.2.1. Germany
16.3. France
16.4. Italy
16.5. Spain
16.6. United Kingdom
16.7. Japan
16.7.1. MHLW
17. Appendix
17.1. Bibliography
17.2. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
 
20. About DelveInsight

Anal Cancer Market

Anal Cancer Market Insight, Epidemiology And Market Forecast - 2034

DelveInsight's Anal Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Anal Cancer, historical and forecasted epidemiology as well as the Anal Cancer market trends in 7MM.